Ye.V. Tikhomirova, Vysakh Balan, Ye.V. Kruchinina, P. Balan, S. Orlova, Y. Titchenko, Ye.A. Levkovich, V. Yatsyuk
{"title":"The Effectiveness of the Dosed Cream Acilact Duo in Patients with Bacterial Vaginosis","authors":"Ye.V. Tikhomirova, Vysakh Balan, Ye.V. Kruchinina, P. Balan, S. Orlova, Y. Titchenko, Ye.A. Levkovich, V. Yatsyuk","doi":"10.33978/2307-3586-2023-19-7-6-12","DOIUrl":null,"url":null,"abstract":"Bacterial vaginosis is a clinical condition in which the normal vaginal microflora, predominantly lactobacilli, is replaced by other microorganisms, mainly anaerobes. The goal of treating bacterial vaginosis is to restore the normal microflora of the vagina, to delay the growth of microorganisms that are not characteristic of this vaginal microcenosis. The purpose of the study was to evaluate the effectiveness of various methods of combined two-stage treatment of bacterial vaginosis in women of reproductive age. Material and methods. The study included 50 patients aged 18 to 45 years (mean age 29.6 ± 4.5 years) with bacterial vaginosis. The first group consisted of 25 patients who received Clindamycin 2% cream for 7 days, dose vaginally at night. For the second stage of therapy in this 1 group, acidophilus bacteria + vitamin-mineral-protein-peptide complex Superlimfly (Acylact Duo) were used, suppository time per day at night intravaginally for 10 days. The second group consisted of 25 patients who received Clindacimin cream for 7 days, dose vaginally at night. For the second stage of therapy, a preparation containing a lyophilized culture of lactobacilli L. casei rhamnosus Doderleini was used, at least 1 × 108 CFU, capsule in the vagina at night for 14 days. Results. The effectiveness of BV therapy was 49% (n = 46). The duration of remission was 24.1 ± 2.1 days (n = 24) in the group of women receiving adjuvant therapy with Acilact Duo dosed cream, and 19.9 ± 2 3. days (n = 22) in the comparison group. In all patients, the average vaginal pH before therapy was 5.5 ± 0.4. In group1 participants, after therapy, the pH was 4.54 ± 0.143 , in group 2 patients, the average vaginal pH was 4.976 ± 0.241. Among the patients of both groups, vaginal dysbiosis of varying severity was detected before treatment (normocenosis was not detected). After therapy, in patients of group, normocenosis of the vagina was achieved in 88% (22/25), in participants of group 2, normocenosis was noted in 72% (18/25). At visit (in 45 days) in women of the group 1 84% (21/25), in the participants of the group 2 – normocenosis was noted in 64% (16/25). Conclusions. Acidophilic bacteria + vitamin-mineral-protein-peptide complex Superlymfly (in which dosed Acylact Duo) quickly restores the optimal acidity of the vagina (pH value) and promotes the growth of the number of beneficial lactobacilli, as a result of which it creates an optimal and natural microflora that prevents the appearance of dysbiosis in patients of reproductive age","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"5 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Effective Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33978/2307-3586-2023-19-7-6-12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Bacterial vaginosis is a clinical condition in which the normal vaginal microflora, predominantly lactobacilli, is replaced by other microorganisms, mainly anaerobes. The goal of treating bacterial vaginosis is to restore the normal microflora of the vagina, to delay the growth of microorganisms that are not characteristic of this vaginal microcenosis. The purpose of the study was to evaluate the effectiveness of various methods of combined two-stage treatment of bacterial vaginosis in women of reproductive age. Material and methods. The study included 50 patients aged 18 to 45 years (mean age 29.6 ± 4.5 years) with bacterial vaginosis. The first group consisted of 25 patients who received Clindamycin 2% cream for 7 days, dose vaginally at night. For the second stage of therapy in this 1 group, acidophilus bacteria + vitamin-mineral-protein-peptide complex Superlimfly (Acylact Duo) were used, suppository time per day at night intravaginally for 10 days. The second group consisted of 25 patients who received Clindacimin cream for 7 days, dose vaginally at night. For the second stage of therapy, a preparation containing a lyophilized culture of lactobacilli L. casei rhamnosus Doderleini was used, at least 1 × 108 CFU, capsule in the vagina at night for 14 days. Results. The effectiveness of BV therapy was 49% (n = 46). The duration of remission was 24.1 ± 2.1 days (n = 24) in the group of women receiving adjuvant therapy with Acilact Duo dosed cream, and 19.9 ± 2 3. days (n = 22) in the comparison group. In all patients, the average vaginal pH before therapy was 5.5 ± 0.4. In group1 participants, after therapy, the pH was 4.54 ± 0.143 , in group 2 patients, the average vaginal pH was 4.976 ± 0.241. Among the patients of both groups, vaginal dysbiosis of varying severity was detected before treatment (normocenosis was not detected). After therapy, in patients of group, normocenosis of the vagina was achieved in 88% (22/25), in participants of group 2, normocenosis was noted in 72% (18/25). At visit (in 45 days) in women of the group 1 84% (21/25), in the participants of the group 2 – normocenosis was noted in 64% (16/25). Conclusions. Acidophilic bacteria + vitamin-mineral-protein-peptide complex Superlymfly (in which dosed Acylact Duo) quickly restores the optimal acidity of the vagina (pH value) and promotes the growth of the number of beneficial lactobacilli, as a result of which it creates an optimal and natural microflora that prevents the appearance of dysbiosis in patients of reproductive age